Medical treatment revolves mainly around mTOR inhibitors, these are primarily used in hereditary renal angiomyolipomas associated with TSC or pulmonary lymphangioleiomyomatosis, which make them out of the question for this patient [15]. This evidence concerns the gene MTOR and kidney angiomyolipoma.